[Changes in Plasma Amyloid-β Level and Their Relationship With White Matter Microstructure in Patients With Mild

Chen-Chen Li1, Xia Zhou1, Wen-Hao Zhu1

  • 1Department of Neurology,The First Affiliated Hospital of Anhui Medical University,Hefei 230022,China.

Insights

Plasma amyloid-beta (Aβ) levels differ between amnesic and vascular mild cognitive impairment. White matter integrity is associated with Aβ levels, showing regional specificity in early dementia stages.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Radiology

Context:

  • Mild cognitive impairment (MCI) is categorized into amnesic (aMCI) and vascular (vMCI) subtypes, each with distinct underlying pathologies.
  • Understanding the biochemical and microstructural differences between aMCI and vMCI is crucial for early diagnosis and targeted treatment.
  • Plasma amyloid-beta (Aβ) levels and white matter integrity, assessed via diffusion tensor imaging (DTI), are potential biomarkers for cognitive decline.

Purpose:

  • To investigate differences in plasma Aβ42 and Aβ40 levels between aMCI and vMCI patients and healthy controls (HC).
  • To examine the relationship between plasma Aβ levels and white matter microstructure (fractional anisotropy and mean diffusivity) in aMCI and vMCI.
  • To identify specific white matter regions affected in each MCI subtype and their correlation with plasma Aβ.

Summary:

  • Plasma Aβ40 levels were elevated in vMCI compared to HC, and Aβ42/40 ratios were lower in vMCI than aMCI.
  • Vascular MCI showed reduced fractional anisotropy and increased mean diffusivity in several white matter tracts, including the internal capsule and superior fronto-occipital fasciculus.
  • Amensic MCI also exhibited white matter microstructural changes, particularly in the posterior limb of the internal capsule and cingulum.
  • Plasma Aβ42/40 levels correlated with specific white matter integrity measures in both aMCI and vMCI, indicating regional specificity.

Impact:

  • This study highlights distinct plasma Aβ profiles and white matter microstructural alterations in aMCI and vMCI.
  • The findings suggest that plasma Aβ levels are associated with white matter integrity, offering potential biomarkers for differentiating MCI subtypes.
  • Identifying regional specificity in white matter damage and its link to plasma Aβ can inform the development of early diagnostic tools and therapeutic strategies for cognitive impairment.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
517
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
139
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212